As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection As anticipated, an End of Phase 2.
Acurx Pharmaceuticals, Inc. announced positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from the Company s recently completed Phase 2b clinical.
Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin.
All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure at end of treatment remained free of C. difficile Infection recurrence through one month after EOT, for a Sustained.
In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary.